Celldex Therapeutics, Inc. (NASDAQ:CLDX) subtracted -$0.05 to its price during the regular trading session on Wednesday, reaching $0.60. When it comes to volume, 3.25 million shares of this company’s common stock changed hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has experienced a 1-year low price of $0.58 and a 1-year high price of $3.26. This organization’s current debt-to-equity ratio is 0.00, its current ratio is 5.50 and its quick ratio is 5.50 at the time of writing. The company has a beta of 2.63.
H.C. Wainwright Resumed shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) to a Buy rating in a report posted on Tuesday, August 1st, 2017. At the present, they have a price target for the Biotechnology set at $10. Several additional equities analysts have also published recent reports on CLDX stock. Aegis Capital, for example, Initiated Celldex Therapeutics, Inc. to Buy in a report that was made public on Monday, November 7th, 2016. Jefferies Downgrade on Celldex Therapeutics, Inc. in a report from Tuesday, March 8th, 2016, while giving the stock to a Hold rating from a Buy rating. In a report sent out on Monday, March 7th, 2016, Wedbush Downgrade the stock rating on Celldex Therapeutics, Inc. from a Outperform to a Neutral. Lastly, from a Outperform rating to Mkt Perform rating on shares of Celldex Therapeutics, Inc. was Downgrade by Leerink Partners on the company’s stock. In total, 3 Wall Street analysts have given this stock a hold rating, with 1 analysts rating it as a strong buy. At the time of writing, this stock has a consensus price target set at $4.13 and average analyst rating set to Hold.
There is a technical analysis indicator called the Relative Strength Index, or RSI, and analysts use it to measure momentum within a range of 0 to 100. When a stock’s RSI falls under 30, it is considered to be oversold. For Celldex Therapeutics, Inc., specifically, the RSI metric has reached 37.14. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has lost -76.43% in value over the last three months, and -79.76% over the last six-month period. Over the last full year, the stock price has lost -73.75%.
The measurement of a stock’s predictable daily price range is referred to as volatility – and it’s also the price range within which a day trader does his or her business. Higher volatility translates to higher losses or profits. After recently verifying the number, Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock has a volatility measurement of 5.37% for the week, with 5.62% volatility as observed from the past 30 days. The public company has 145.06M shares outstanding currently, as well as a market cap of $87.20M. This stock’s distance from its 20-day simple moving average is -7.17%, based on a recent bid, while its distance from the 50-day simple moving average is currently -37.05%. Meanwhile, it has a distance of -73.43% from the 200-day simple moving average. Today, this organization is sitting -81.56% away from its 52-week high price and 3.62% away from its 52-week low price.
More detail-oriented stock traders might be keeping tabs on another metric: the Williams Percent Range or Williams %R. The Williams %R measurement is a widely-used technical indicator founded by Larry Williams to enable the identification of oversold and overbought stock territory. Traders will typically use Williams %R alongside other trend indicators to help locate potential turning points in a stock’s price trajectory. Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s Williams Percent Range, or 14-day Williams %R, is sitting at 85.71 at the time of writing. Generally speaking, if the indicator rises above -20, the shares may be overbought. On the flip side, if the indicator goes below -80, it may mean that the stock has crossed over into oversold territory.
Investors oftentimes keep their eyes on the latest stock price support and resistance levels. The support is a lower “floor” level where a stock may bounce back after it has dipped. If the share price can penetrate the first support level, investor attention may shift to the second level. The resistance is the contrary of support levels. As a stock grows in value, it may see a dip once it reaches a specific level of resistance. After a recent examination, this company’s shares’ first resistance level is sitting at 0.63. Meanwhile, investors are looking out for the first support level, which is 0.58.